Other
Other liabilities
Vertex Pharmaceuticals Other liabilities decreased by 78.2% to $23.10M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 5.0%, from $22.00M to $23.10M. Over 3 years (FY 2021 to FY 2025), Other liabilities shows an upward trend with a 106.8% CAGR.
Analysis
StatementIncome Statement
SectionOther
CategoryLiquidity
SignalContext dependent
VolatilityModerate
First reportedQ1 2017
Last reportedQ1 2026May 5, 2026
How to read this metric
Fluctuations reflect changes in operational accruals and deferred income, which can impact short-term cash flow availability.
Detailed definition
The net change in miscellaneous short-term and long-term liabilities not classified as accounts payable or debt. These o...
Peer comparison
Commonly reported in cash flow statements; varies based on specific business model accruals.
Metric ID:
other_increase_decrease_in_other_operating_liabilitiesHistorical Data
19 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$54.30M | -$21.30M | $84.10M | $15.70M | -$47.40M | -$9.00M | $539.60M | $52.23M | $52.23M | $52.23M | $52.23M | $167.60M | -$256.60M | $134.10M | $22.00M | -$63.20M | $83.90M | $105.80M | $23.10M |
| QoQ Change | — | +60.8% | +494.8% | -81.3% | -401.9% | +81.0% | >999% | -90.3% | +0.0% | +0.0% | +0.0% | +220.9% | -253.1% | +152.3% | -83.6% | -387.3% | +232.8% | +26.1% | -78.2% |
| YoY Change | — | — | — | — | +12.7% | +57.7% | +541.6% | +232.6% | +210.2% | +680.3% | -90.3% | +220.9% | -591.3% | +156.8% | -86.9% | +75.4% | -37.4% | — | +5.0% |
Range-$256.60M – $539.60M
CAGR-17.3%
Avg YoY Growth+99.1%
Median YoY Growth+66.6%
Other liabilities at Other Companies
Frequently Asked Questions
- What is Vertex Pharmaceuticals's other liabilities?
- Vertex Pharmaceuticals (VRTX) reported other liabilities of $23.10M in Q1 2026.
- How has Vertex Pharmaceuticals's other liabilities changed year-over-year?
- Vertex Pharmaceuticals's other liabilities increased by 5.0% year-over-year, from $22.00M to $23.10M.
- What is the long-term trend for Vertex Pharmaceuticals's other liabilities?
- Over 3 years (2021 to 2025), Vertex Pharmaceuticals's other liabilities has grown at a 106.8% compound annual growth rate (CAGR), from $16.80M to $148.50M.
- What does other liabilities mean?
- The change in various non-debt operational liabilities that do not fall under standard accounts payable.